Regulatory exclusivity
Sector Deep DivesProtection from competition granted by a medicines regulator, running separately from patent protection.
Exclusivity is granted by the regulator rather than the patent office, and it blocks a competitor from relying on the originator's trial data or from being approved at all for a defined period.
It runs in parallel with patents and sometimes outlasts them. In the EU the standard framework gives eight years of data exclusivity plus two of market protection, and orphan designation adds a further period for rare disease treatments.
The practical consequence is that the effective end of protection is the later of patent expiry and exclusivity expiry, so modelling patents alone can put the cliff in the wrong year.
Additional extensions exist for supplementary protection certificates and for completing paediatric studies, which is why establishing a product's true loss of exclusivity date is a genuine diligence exercise rather than a lookup.
Worked example
A drug's European patent expires in 2029, but it was approved in 2023 with eight years of data exclusivity and two of market protection.
Protection therefore runs to 2033, four years beyond the patent. Modelling the patent alone would put the cliff in the wrong year and understate the asset by billions.
Establishing the true loss of exclusivity date, including any paediatric extension or supplementary protection certificate, is a genuine diligence exercise rather than a lookup.